Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Systemic Inflammatory Response And Nutritional Biomarkers As Predictors Of Nivolumab Efficacy For Gastric Cancer

T. Namikawa, K. Yokota, Nobuhisa Tanioka, Ian Fukudome, J. Iwabu, M. Munekage, Sunao Uemura, H. Maeda, H. Kitagawa, M. Kobayashi, K. Hanazaki
Published 2020 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Purpose To investigate the usefulness of clinicopathological systemic inflammatory response and nutritional biomarkers for predicting the efficacy of nivolumab in patients with advanced gastric cancer. Methods The subjects of this study were 29 patients who received nivolumab treatment for advanced gastric cancer at the Kochi Medical School between 2017 and 2019. Clinicopathological information, including systemic inflammatory response data, were obtained to investigate the associations between baseline cancer-related prognostic variables and survival outcomes. Results Immune-related adverse events (irAEs) of any grade were identified in 34.5% (10/29) of the patients. The median progression-free survival of patients with irAEs was significantly greater than that of patients without irAEs (5.8 months vs. 1.2 months, respectively; P  = 0.028). The neutrophil to lymphocyte ratio (NLR) after 4 weeks of treatment in the complete response (CR) or partial response (PR) group was significantly lower than that in the stable disease (SD) or progression disease (PD) group (2.2 vs. 2.9, respectively; P  = 0.044). The prognostic nutrition index (PNI) before treatment in the CR or PR group was significantly higher than that in the SD or PD group (37.1 vs. 32.1, respectively; P  = 0.011). The PNI 8 weeks after treatment and the Glasgow prognostic score (GPS) before treatment were significantly associated with a poor outcome. Conclusion The irAE, NLR, PNI, and GPS may be useful predictive markers for nivolumab efficacy in patients with advanced gastric cancer.
This paper references
( Ver . 4 )
K Shitara
10.1002/jso.25057
The value of inflammation based prognostic scores in patients undergoing surgical resection for oesophageal and gastric carcinoma
Jiaxin Wen (2018)
refrac - tory or intolerant to fluoropyrimidines , platinum , taxanes , and irinotecan
Brahmer (2018)
10.1186/s40792-018-0479-3
Successful treatment of liver metastases arising from early gastric cancer achieved clinical complete response by nivolumab
T. Namikawa (2018)
10.1007/s10120-016-0622-4
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Japanese Gastric Cancer Association (2016)
10.1159/000342376
Comparison of Two Inflammation-Based Prognostic Scores in Patients with Unresectable Advanced Gastric Cancer
Jaeheon Jeong (2012)
Global Burden of Disease Cancer Collaboration
C Fitzmaurice (2013)
10.1111/APM.1965.64.1.31
THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO-CALLED INTESTINAL-TYPE CARCINOMA. AN ATTEMPT AT A HISTO-CLINICAL CLASSIFICATION.
P. Laurén (1965)
10.1007/s00280-018-3569-9
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
Sakura Iizumi (2018)
10.1016/S0140-6736(17)31827-5
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Y. Kang (2017)
10.1001/jamaoncol.2019.3531
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
D. Ilson (2019)
10.1200/JCO.2019.37.15_SUPPL.4049
Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
K. Masuda (2019)
10.1007/s10120-018-0892-0
CRP/prealbumin, a novel inflammatory index for predicting recurrence after radical resection in gastric cancer patients: post hoc analysis of a randomized phase III trial
J. Lu (2018)
10.1200/JCO.2012.41.6750
Management of immune-related adverse events and kinetics of response with ipilimumab.
J. Weber (2012)
10.7314/APJCP.2014.15.2.945
Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
Q. Li (2014)
10.1007/s10120-019-00970-8
Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer
T. Satoh (2019)
10.1159/000446373
Evaluation of Systemic Inflammatory Response Biomarkers in Patients Receiving Chemotherapy for Unresectable and Recurrent Advanced Gastric Cancer
T. Namikawa (2016)
10.1126/science.1217718
The Inhibitory Receptor PD-1 Regulates IgA Selection and Bacterial Composition in the Gut
S. Kawamoto (2012)
10.1245/s10434-016-5272-6
Low Preoperative Prognostic Nutritional Index Predicts Poor Survival Post-gastrectomy in Elderly Patients with Gastric Cancer
PhD Katsunobu Sakurai MD (2016)
10.1007/s10120-018-0825-y
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan
C. Kondoh (2018)
10.1056/NEJMoa1200694
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
J. Brahmer (2012)
10.1007/s10120-018-00922-8
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
A. Sasaki (2018)
10.1002/jso.25793
Systemic inflammatory dynamics during chemoradiotherapy predict response, relapse, metastasis, and survival in esophageal carcinoma
A. Sherry (2019)
10.1007/s10120-017-0694-9
Gastric cancer: Asia and the world
T. Sano (2017)
Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced
J Lu (2019)
10.1007/s10147-018-1250-2
Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
A. Nakaya (2018)
10.1007/s10120-018-0897-8
Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer
T. Namikawa (2018)
10.1093/annonc/mdy540
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)
N. Boku (2019)
10.1007/s10120-018-0899-6
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2)
K. Kato (2018)
patients : post hoc analysis of a randomized phase III trial
JX Lin (2019)
10.1007/s00595-009-4065-y
Prognostic nutritional Index: A tool to predict the biological aggressiveness of gastric carcinoma
T. Nozoe (2009)
10.1001/jamaoncol.2017.2925
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
K. Haratani (2018)
10.1038/nature13480
Comprehensive molecular characterization of gastric adenocarcinoma
A. Bass (2014)
10.1001/jamaoncol.2015.0735
The Global Burden of Cancer 2013.
C. Fitzmaurice (2015)
10.1186/s12885-018-4201-4
Prognostic nutritional index as a predictor of survival in resectable gastric cancer patients with normal preoperative serum carcinoembryonic antigen levels: a propensity score matching analysis
N. Hirahara (2018)
10.1186/s40425-019-0514-3
Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer
Saori Mishima (2019)
10.1007/s10120-016-0609-1
Conversion therapy for gastric cancer: who can make conversion as successful as Goromaru?
M. Terashima (2016)
10.1097/MCO.0b013e32832a7902
Systemic inflammation, nutritional status and survival in patients with cancer
D. McMillan (2009)
10.1634/theoncologist.2017-0384
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Yukihiro Toi (2018)
10.21037/JGO.2019.05.07
Delivery rate of patients with advanced gastric cancer to third-line chemotherapy and those patients' characteristics: an analysis in real-world setting.
M. Ueno (2019)
10.1016/S1470-2045(18)30739-3
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
K. Shitara (2018)
10.1002/9781118696194.ch1.1
Global Burden of Cancer
X. Ma (2006)
10.18632/oncotarget.26145
Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study
T. Ogata (2018)
10.1007/s00384-006-0259-6
Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer
D. McMillan (2006)
10.1186/s12885-019-6466-7
Complete blood count-based inflammatory score (CBCS) is a novel prognostic marker for gastric cancer patients after curative resection
J. Lin (2020)
Predictive factors for hyperprogressive disease during nivolumab as anti - PD 1 treatment in patients with advanced
S Iizumi (2019)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar